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Introduction 
Several embryonic mechanisms have been 
described to be reactivated during tumour 
progression to serve cancer purposes. For 
example, epithelial-mesenchymal 
transition (EMT) allows cancer cells to 
invade, inducing metastasis. It is like 
disggregate epithelial structure in order to 
cells acquire the capacity of movement. 
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Conclusions 
Genetic instability  activation of EMT inducers 
Even CIS but already EMT  implications not just for metastasis 
Quicker dissemination as they are already motile when basal 
membrane is disrupted  prediction of agresiveness 
New insight in cancer = developmental point of view 
Reactivated developmental mechanisms  molecules or pathways  
implicated are possible target for novel therapies (highly specifics) 
Table 1. It shows proposed correspondences or relation of hallmarks of cancer with development processes  
Ability to 
invade and 
disseminate 
Loss of 
apicobasal 
polarity 
Loss of 
cellular 
adhesion 
Switch of 
cadherins, 
integrins and 
cytoeskeletal 
elements  
Underlying 
basal 
membrane 
is degraded Functional loss of E-cadherin is considered a hallmark of EMT and 
TGF-beta signalling pathway the primary inducer of EMT, as it induces 
E-cadherin repressors (Snail, Slug, SIP1). 
HALLMARK CANCER DEVELOPMENT 
Sustaining Proliferative Signalling Oncogens Morphogens 
Evading Growth Suppressors Tumour suppressor genes 
(TSG) 
Morphogens 
Resisting Cell Death  No functional p53 p53 is dispensable 
Enabling Replicative Immortality  Telomerase activation Telomere elongation 
Inducing Angiogenesis Leaking and aberrant 
vessels, erratic blood flow 
Controlled, closed and 
correct blood flow 
Activating Invasion and Metastasis  EMT EMT 
Figure 3. TEB oncogenic transformation. Due to genetic alterations EMT 
inducers are expressed without any control. Cells are able to invade adjacent 
stroma and disseminate to spread throughout the body by blood vessels. Ref. (2) 
TEB 
•Induced by steroids at puberty; RTK signalling – shared with EMT 
•High proliferation rate  high probability of mutations and more 
sensitive to carcinogens   sites of malignization in breast cancer  
• Multilayered epithelial structure: luminal (polar), basal (myoepithelial) and internal 
• Give rise to the bilayered mammary ducts (lobuloalveolar units, LAU) 
• Elongation of the ducts depends on proliferation within the TEB, where cells 
exhibit mesenchymal characteristics (epithelial plasticity): lacking contact with 
lumen or basal membrane, cell adhesion and apicobasal polarity 
Introduction 
Conclusions 
Figure 1. 
Epithelial 
Mesenchymal 
Transition. More 
relevant changes 
in features and 
molecules are 
shown, 
displaying the 
conversion from 
epithelial to 
mesenchymal 
phenotype. 
Ref.(1) 
Figure 2. TEB structure. At the onset of puberty, 
at the end of mammary gland ducts terminal end 
buds (TEB) are stablished, showing a 
multilayered epithelial structure. Ref. (1) 
